Pulmatrix, Inc. current report, 11 February 2021

Pulmatrix, Inc. 8-K Summary

Business Context and Reporting Period

This Form 8-K Current Report, dated February 11, 2021, details a material definitive agreement entered into by Pulmatrix, Inc. (NASDAQ: PULM). The filing reports on a registered direct offering of common stock executed on February 11, 2021, with the offering closing on February 16, 2021.

Key Financial Metrics and Transaction Details

  • Offering Size: 20,000,000 shares of Common Stock.
  • Offering Price: $2.00 per share.
  • Gross Proceeds: $40.0 million (calculated from share count and price).
  • Net Proceeds: Approximately $37.1 million after deducting fees and expenses.
  • Placement Agent Fees: 7.0% of gross proceeds plus $75,000 for non-accountable expenses and $15,950 for clearing expenses.
  • Placement Agent Warrants: Warrants to purchase up to 1,300,000 shares at an exercise price of $2.50 per share, exercisable immediately with a five-year term.
  • Use of Proceeds: Working capital and general corporate purposes.

Material Changes

The filing represents a significant capital raise event. The company issued 20,000,000 new shares of common stock, increasing the outstanding share count. Additionally, the company granted unregistered warrants to the placement agent, H.C. Wainwright & Co., LLC, subject to beneficial ownership limitations (4.99% standard, up to 9.99% with notice).

Outlook, Risks, and Management Commentary

Management intends to utilize the net proceeds for working capital and general corporate purposes. The filing incorporates by reference press releases issued on February 11 and February 16, 2021, regarding the offering and its closing. The Placement Agent Warrants are issued under Section 4(a)(2) and Regulation D exemptions and are not registered under the Securities Act of 1933.

Investor Verification Checklist

  • Verify the exact number of shares outstanding post-offering to assess dilution impact.
  • Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants or restrictions.
  • Confirm the exercise terms and beneficial ownership limitations of the Placement Agent Warrants (Exhibit 4.1).
  • Check subsequent filings for the actual closing date confirmation and final net proceeds received.